Boston, MA -- (SBWIRE) -- 09/13/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (Carbonite Inc (NASDAQ:CARB), Endeavour Silver Corp. (CAN) (NYSE:EXK), Universal Display Corporation (NASDAQ:OLED), Inovio Pharmaceuticals Inc (NYSEMKT:INO)
Carbonite Inc (NASDAQ:CARB) shares dropped 10.07% and closed at $14.82 in the last trading session. The company on Sept. 3 announced that it will enter into Business Associate Agreements with HIPAA-compliant businesses, providing the healthcare industry with secure access to cloud backup services. Carbonite it is one of the first cloud backup vendors to announce its compliance with the new federal HIPAA regulations, which become effective on September 23, 2013.
Is CARB A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Endeavour Silver Corp. (CAN) (NYSE:EXK) shares decreased 9.05% to $4.22. The company on Sept. 11 announced that exploration drilling at the Company's El Cubo mine in Guanajuato State, Mexico has intersected high grade gold-silver mineralization in two veins near historic mine workings in the Asunción area of the Villalpando vein system. Drilling intersected strong mineralization in both the Villalpando vein and the Asunción vein.
Is EXK A Good Buy After The Recent Price Movement? Find Out Here
Universal Display Corporation (NASDAQ:OLED) shares dropped 9.04% and closed at $32.18 in the last trading session. The company announced that the Company will present at the Oppenheimer Emerging Innovations Conference on September 17, 2013 in New York, NY. To see how Universal Display is changing the face of the display and lighting industries with its UniversalPHOLED®, white OLED and flexible OLED technologies, please visit the company at www.universaldisplay.com.
How Should Investors Trade OLED After The Recent Volatility? Get Free Report Here
Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares decreased 8.98% to $2.23. Roche (six:RO)(six:ROG)(otcqx:RHHBY) and Inovio Pharmaceuticals, Inc. on Sept. 10 announced that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B. The licensed compounds are currently in preclinical development and have generated robust T-cell responses in animal models.
How Should Investors Trade INO After The Recent Volatility? Get Free Report Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)